Press Releases
Media Contact:
Lorie Calvo
425-608-3008
lcalvo@nwbio.com
Northwest Biotherapeutics Presents New Data on its Approach for the Treatment of Solid Tumors
Bothell, Washington - June 18, 2003 - Northwest Biotherapeutics, Inc. (NWBT.OB) today announced that it presented new, positive data from the evaluation of its DCVax®-Direct Adjuvant Cancer Therapy product candidate at the Fourth International Expert Meeting on Clinical Immunotherapy held in Amsterdam, the Netherlands, on June 13-16, 2003. DCVax®-Direct Adjuvant Cancer Therapy is designed to be a single therapeutic for all solid tumors.
"This new animal model data is very encouraging," stated Dr. Marnix Bosch, the Company's vice president of vaccine development. "It confirms our earlier animal data showing the regression of solid tumors injected with DCVax®-Direct in combination with chemotherapy. The data also suggests that DCVax®-Direct generates an active immunity in the animal that prevents the establishment of secondary tumors." Dr. Bosch's presentation also contained new information that this immunization effect is dependent on the maturation state of the injected dendritic cells.
Dr. Bosch further stated, "Immature dendritic cells do not prove capable of creating long-term immunization in our model. However, partially mature dendritic cells appear to confer longer term protection in the animal against further tumor establishment and growth. This has important implications for the significance of our recently unveiled tangential flow filtration manufacturing system. It is less costly than traditional approaches for generating dendritic cells and it allows us to control dendritic cell maturation to generate the partially mature cells showing the most therapeutic potential."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. The Company's strategy is to combine its expertise in dendritic cell biology, immunology and antigen discovery with its proprietary technologies to develop cancer therapies. The Company's lead product candidate, DCVax®-Prostate has completed Phase I/II clinical trials. As part of its strategy, it is further developing diagnostic and therapeutic antibodies against its proprietary cancer targets and it is continuing refinement of its next generation system for cost effectively producing high purity dendritic cells and dendritic cell precursors for potential new cancer products.
Statements made in this news release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, the timely performance of third parties and the Company's recent cost-cutting initiatives and the direct and indirect consequences of those initiatives. Additional information on these and other factors, which could affect the Company's results, are included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
DCVax® is a registered trademark of Northwest Biotherapeutics, Inc. All rights are reserved.
|
